Day One Biopharmaceuticals/$DAWN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Day One Biopharmaceuticals

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

Ticker

$DAWN
Sector
Health
Primary listing
NASDAQ

Employees

182
Headquarters
Brisbane, United States
Website
dayonebio.com

DAWN Metrics

BasicAdvanced
$742M
-
-$0.94
-1.27
-

What the Analysts think about DAWN

Analyst ratings (Buy, Hold, Sell) for Day One Biopharmaceuticals stock.

Bulls say / Bears say

OJEMDA™ posted net product revenue of $33.6 million in Q2 2025, a 310% year-over-year jump and a 10% sequential increase, showing accelerating commercial adoption (GlobeNewswire)
The company finished Q2 2025 with $453.1 million in cash and short-term investments, ensuring a solid financial runway for ongoing R&D and commercialization (GlobeNewswire)
Patient enrollment in the pivotal Phase 3 FIREFLY-2 trial remains on schedule for completion in the first half of 2026, demonstrating steady progress in the pipeline (GlobeNewswire)
Despite strong revenue growth, Day One reported a net loss of $30.3 million in Q2 2025, highlighting ongoing lack of profitability (GlobeNewswire)
Research and development expenses remained high at $36.1 million in Q2 2025, reflecting substantial continued investment ahead of any commercial returns (GlobeNewswire)
Pipeline risk remains as DAY301 is still in the Phase 1a stage of its clinical trial, likely several years away from possible approval and commercial launch (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.

DAWN Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

DAWN Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DAWN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs